Quest PharmaTech Inc. is a Canada-based pharmaceutical company. The Company, through its subsidiary, OncoQuest Inc., is developing immunotherapies for cancer treatment. It operates through two segments: biopharmaceutical/pharmaceutical products and consumer/cosmetic products. OncoQuest's technology platform includes a panel of tumor antigen specific monoclonal immunoglobulins, including CA125, MUC1, PSA, and Her2/neu, and the application of combinatorial immunotherapy. OncoQuest's lead product, oregovomab, is undergoing a Phase IIb clinical trial involving approximately 80 ovarian cancer patients in Italy and the United States. OncoQuest's pipeline of product candidates consists of four other monoclonal antibodies targeting certain tumor antigens that are presented in a range of cancers, including such cancers as breast, lung, pancreas, stomach and prostate. It also markets consumer health products around the world, including Bellus Skin serum, an anti-wrinkle skin care product.